Literature DB >> 1735357

Esophageal strictures following endoscopic variceal sclerotherapy. Antecedents, clinical profile, and management.

R Kochhar1, M K Goenka, S K Mehta.   

Abstract

We have evaluated 169 patients with portal hypertension receiving endoscopic variceal sclerotherapy in order to assess the predisposing factors, clinical profile, and treatment response of sclerotherapy-induced esophageal strictures. Of the 129 patients included in the final analysis, 20 (15.5%) developed persistent esophageal stricture. No significant difference was found with respect to age, nature of sclerosant (absolute alcohol, ethanolamine oleate, or sodium tetradecyl sulfate), etiology of portal hypertension, Child's class, initial variceal score, or intensity of sclerotherapy schedule between the patients who developed strictures and those who did not. However, female sex (P less than 0.01) and persistent esophageal ulceration (P less than 0.05) did predispose to stricture formation. Sclerotherapy-induced strictures presented with a variable grade of dysphagia, were always solitary, and were localized to the lower end of esophagus. Most of these could be dilated rapidly using Eder-Puestow metal olives (3.15 +/- 0.80 dilatation sessions per patient). Stricture formation did interrupt an effective sclerotherapy program but only temporarily, and successful variceal obliteration could be obtained after stricture dilatation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735357     DOI: 10.1007/bf01307726

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Endoscopic sclerotherapy for portal hypertension due to extrahepatic obstruction: long-term follow-up.

Authors:  D K Bhargava; M Dwivedi; S Dasarathy; A Arora
Journal:  Gastrointest Endosc       Date:  1989 Jul-Aug       Impact factor: 9.427

2.  Frequent endoscopic variceal sclerotherapy increases risk of complications. Prospective randomized controlled study of two treatment schedules.

Authors:  E Akriviadis; J Korula; S Gupta; Y Ko; S Yamada
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

3.  Factors affecting successful endoscopic sclerotherapy for oesophageal varices.

Authors:  J D Rose; M D Crane; P M Smith
Journal:  Gut       Date:  1983-10       Impact factor: 23.059

4.  Sclerotherapy-associated esophageal ulcers: lessons from a double-blind, randomized comparison of sucralfate suspension versus placebo.

Authors:  N Tabibian; J L Smith; D Y Graham
Journal:  Gastrointest Endosc       Date:  1989 Jul-Aug       Impact factor: 9.427

5.  Endoscopic sclerotherapy versus medical treatment for bleeding esophageal varices in patients with schistosomal liver disease.

Authors:  A el-Zayadi; S S el-Din; S M Kabil
Journal:  Gastrointest Endosc       Date:  1988 Jul-Aug       Impact factor: 9.427

6.  Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial.

Authors:  B R MacDougall; D Westaby; A Theodossi; J L Dawson; R Williams
Journal:  Lancet       Date:  1982-01-16       Impact factor: 79.321

7.  Comparison of the two time schedules for endoscopic sclerotherapy: a prospective randomised controlled study.

Authors:  S K Sarin; G Sachdev; R Nanda; S K Batra; B S Anand
Journal:  Gut       Date:  1986-06       Impact factor: 23.059

8.  Intravariceal versus paravariceal sclerotherapy: a prospective, controlled, randomised trial.

Authors:  S K Sarin; R Nanda; G Sachdev; S Chari; B S Anand; S L Broor
Journal:  Gut       Date:  1987-06       Impact factor: 23.059

9.  Esophageal motility: effects of injection sclerotherapy.

Authors:  G M Larson; D J Vandertoll; D T Netscher; H C Polk
Journal:  Surgery       Date:  1984-10       Impact factor: 3.982

10.  Oesophageal stricture and dysphagia after endoscopic sclerotherapy for bleeding varices.

Authors:  T Sørensen; F Burcharth; M L Pedersen; F Findahl
Journal:  Gut       Date:  1984-05       Impact factor: 23.059

View more
  3 in total

1.  Endoscopic sclerotherapy in porcine esophagus changes luminal cross-sectional area and wall distensibility dose- and time-dependently.

Authors:  J A Petersen; C Djurhuus; J Koff; L Vinter-Jensen; H Gregersen
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

2.  Systemic treatment with recombinant human epidermal growth factor accelerates healing of sclerotherapy-induced esophageal ulcers and prevents esophageal stricture formations in pigs.

Authors:  C O Juhl; L Vinter-Jensen; L S Jensen; E Nexø; J C Djurhuus; E Z Dajani
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

3.  Histologic and manometric studies on the esophagus following endoscopic sclerotherapy.

Authors:  Peeyush Sharma; Inga Hagerstrand; Dave Krishan Sharma
Journal:  Dig Dis Sci       Date:  2008-11-26       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.